CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.

Altre lingue China Resources Double-Crane Pharmaceutical Co.,Ltd.

Azioni

600062

CNE000000Q94

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
19,37 ^CNY	-3,30%		-2,52%	+4,14%

07:54	L'unità farmaceutica Double-Crane ottiene il via libera dalla Cina per il farmaco antinfluenzale	MT
28/06	CR Double-Crane Pharmaceutical registra farmaci antibiotici e contro l'ulcera in Cina	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Double-Crane Pharmaceutical Unit Gets China Nod for Influenza Drug	07:54
CR Double-Crane Pharmaceutical Registers Antibiotic, Ulcer Medications in China	28/06
CR Double-Crane Pharmaceutical Gets Certificate to Market Low-Calcium Dialysis Solution	14/06
CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection	27/05
CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Schizophrenia Drug	23/05
CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection	08/05
CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%	26/04
CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication	26/04
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
CR Double-Crane Pharmaceutical Gets Nod to Trial Semaglutide Injection	16/04
CR Double-Crane Pharma Unit Receives Approval for Epilepsy Drug	26/03
CR Double-Crane Pharma's 2023 Profit Jumps 13%, Operating Income Climbs 6%	22/03
China Resources Double-Crane Pharmaceutical Co.,Ltd. Proposes Cash Dividend	21/03
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
CR Double-crane Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets	12/03
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion.	26/02
CR Double-Crane Pharma Gets Nod for Apixaban Tablets; Unit's Clozapine Orally Disintegrating Tablets Gets Greenlight for Proposed Amendments	21/02
CR Double-Crane Pharma's Unit Gets Nod to Market Lithium Carbonate Drug Ingredient	08/02
CR Double-Crane Pharmaceutical's Unit Gets Nod to Raise Strength of Viagra Drug	31/01
China Includes CR Double-Crane Pharmaceutical's Two Drugs in List of Insurance-Backed Drugs	14/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue China Resources Double-Crane Pharmaceutical Co.,Ltd.

Azioni

600062

CNE000000Q94

Altre lingue

Filtri